{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3568, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "section_divider", "function": "transition", "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/24", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "solution", "function": "present_solution", "notes": "Includes scientific diagrams of molecular pathways and efficacy data charts.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/25", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "traction", "function": "show_traction", "notes": "Layout splits into three quadrants of charts (survival %, tumor response %, median survival days) plus a navy summary band; Immix Biopharma logo top-right and page number 26 bottom-right.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/26", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "traction", "function": "show_traction", "notes": "Includes a process diagram showing the mechanism of action of IMX-110 in tumor microenvironments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/27", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "traction", "function": "show_traction", "notes": "Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor growth.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/28", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/29", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "traction", "function": "show_traction", "notes": "Includes waterfall and spider/line charts for clinical efficacy. Source note at bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/30", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/31", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "traction", "function": "show_traction", "notes": "The chart visualizes a single data point (4 months mPFS at 100% of patients with >=3 prior lines of therapy) as a highlighted marker.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/32", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "roadmap", "function": "plan_implementation", "notes": "Shows two parallel tracks: monotherapy and combination therapy with tislelizumab.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/33", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/34", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a process-flow style layout to connect platform capabilities to specific drug candidates.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/35", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a '3 Pillars' framework to explain the platform's foundation, leading into specific product applications.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/36", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "solution", "function": "present_solution", "notes": "Includes technical diagrams of the drug structure, bar charts for expression, and a Kaplan-Meier survival curve.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/37", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 38, "slideType": "traction", "function": "show_traction", "notes": "Includes two sets of charts: tumor volume over time and survival curves for MDA-MB-231 and HCT-116 models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/38", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 39, "slideType": "solution", "function": "present_solution", "notes": "Includes multiple scientific diagrams and clinical trial data summaries.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/39", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 40, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/40", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-40", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "team_bio", "function": "other", "notes": "The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Selected Nexcella Scientific Advisory Board Members (bottom).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/41", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-41", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 42, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/42", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-42", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 43, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/43", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-43", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 44, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/44", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-44", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 45, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs ($33.4bn vs $0.9bn).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/45", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-45", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "docSlug": "2296286e07283457e97b21dc9ce59469", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 46, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo, likely to frame the market opportunity for IMX-120.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/46", "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0", "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-46", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": "https://imgproxy.kitesheet.com/zIDQMdphoDZCZLvJ7IpcwMwbmZ-6n6rFg98GNRJwz4o/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82M2VjOGU3NzNjOWI0M2U3YjAzM2I2NDE2NzAyNjExNC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/1", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/svCuhHHtW0q1xcu_jV22YfSzkx2t2HT_ISWCs0mcQA4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82M2VjOGU3NzNjOWI0M2U3YjAzM2I2NDE2NzAyNjExNC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/qE3ySdjP0gGJCG_FzsHoETmKymYsohI7D5wv3k2mq7M/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82M2VjOGU3NzNjOWI0M2U3YjAzM2I2NDE2NzAyNjExNC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/231x-i0uo4aCI2Qu-0Ft2Y3Iu2qHT0hHDPwvAaOG9vk/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82M2VjOGU3NzNjOWI0M2U3YjAzM2I2NDE2NzAyNjExNC9wMDAxLnBuZw" }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/2", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a numbered list format to present key value propositions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/3", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "market_sizing", "function": "size_opportunity", "notes": "The slide uses a wave-like visual to represent market segments and their associated financial opportunities.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/4", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 4, "beatId": "7e39c9fb-0b86-4bb6-912e-beac97980ce4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Description of market opportunity and current limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 5, "from": 4, "beatId": "daf47eb1-67eb-4ebe-ad97-0646cd1f6f9d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Discussion of market potential", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide highlights NXC-201's superior efficacy (100% response rate) and safety profile (zero neurotoxicity) compared to existing therapies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/5", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 4, "beatId": "7e39c9fb-0b86-4bb6-912e-beac97980ce4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Description of market opportunity and current limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 5, "from": 4, "beatId": "daf47eb1-67eb-4ebe-ad97-0646cd1f6f9d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Market Size", "beatSlug": "sequoia-pitch-market-size", "evidence": "Discussion of market potential", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" }, { "to": 8, "from": 5, "beatId": "e6497832-3875-42e3-a439-0b6eba51fc60", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competition", "beatSlug": "sequoia-pitch-competition", "evidence": "Competitive analysis of existing therapies", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that these are cross-trial comparisons and not head-to-head studies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/6", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 4, "beatId": "7e39c9fb-0b86-4bb6-912e-beac97980ce4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Description of market opportunity and current limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 8, "from": 5, "beatId": "e6497832-3875-42e3-a439-0b6eba51fc60", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competition", "beatSlug": "sequoia-pitch-competition", "evidence": "Competitive analysis of existing therapies", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a table structure to contrast standard of care with the company's target segment. The bottom section uses bar charts to imply relative patient population growth.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/7", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 4, "beatId": "7e39c9fb-0b86-4bb6-912e-beac97980ce4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Description of market opportunity and current limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 8, "from": 5, "beatId": "e6497832-3875-42e3-a439-0b6eba51fc60", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competition", "beatSlug": "sequoia-pitch-competition", "evidence": "Competitive analysis of existing therapies", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly warns about cross-trial comparison limitations in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/8", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 9, "from": 4, "beatId": "7e39c9fb-0b86-4bb6-912e-beac97980ce4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Description of market opportunity and current limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 8, "from": 5, "beatId": "e6497832-3875-42e3-a439-0b6eba51fc60", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Competition", "beatSlug": "sequoia-pitch-competition", "evidence": "Competitive analysis of existing therapies", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "pain_points", "function": "frame_problem", "notes": "The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/9", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-9", "loopMatches": [ { "to": 10, "from": 9, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "725f84c4-bd91-4b6a-a917-fa8ab5f5f3e9", "evidence": "Neurotoxicity restricts CAR-T adoption", "position": 0, "objective": "What is the cost of not adopting Immix Biopharma's therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 9, "from": 4, "beatId": "7e39c9fb-0b86-4bb6-912e-beac97980ce4", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Description of market opportunity and current limitations", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "Includes a cartoon liver character at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/10", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-10", "loopMatches": [ { "to": 10, "from": 9, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "725f84c4-bd91-4b6a-a917-fa8ab5f5f3e9", "evidence": "Neurotoxicity restricts CAR-T adoption", "position": 0, "objective": "What is the cost of not adopting Immix Biopharma's therapies?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes a footer citing FDA approval precedents for similar patient population sizes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/11", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "traction", "function": "show_traction", "notes": "Includes detailed clinical trial citations in the footer.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/12", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "roadmap", "function": "show_traction", "notes": "The slide uses a standard pharmaceutical pipeline table format.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/13", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a two-column layout to track progress for two distinct drug programs.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/14", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a side-by-side comparison of two proprietary platforms.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/15", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-15", "loopMatches": [ { "to": 18, "from": 15, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "ec7f8eed-93e3-495e-a456-08be8d6fdcb8", "evidence": "NXC-201 entering large markets at a pivotal moment", "position": 1, "objective": "Why now for Immix Biopharma's therapies?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "transition", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/16", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-16", "loopMatches": [ { "to": 18, "from": 15, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "ec7f8eed-93e3-495e-a456-08be8d6fdcb8", "evidence": "NXC-201 entering large markets at a pivotal moment", "position": 1, "objective": "Why now for Immix Biopharma's therapies?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "solution", "function": "present_solution", "notes": "Includes comparative charts for transduction efficiency and anti-exhaustion capability.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/17", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-17", "loopMatches": [ { "to": 18, "from": 15, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "ec7f8eed-93e3-495e-a456-08be8d6fdcb8", "evidence": "NXC-201 entering large markets at a pivotal moment", "position": 1, "objective": "Why now for Immix Biopharma's therapies?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "why_now", "function": "argue_timing", "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/18", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-18", "loopMatches": [ { "to": 18, "from": 15, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "ec7f8eed-93e3-495e-a456-08be8d6fdcb8", "evidence": "NXC-201 entering large markets at a pivotal moment", "position": 1, "objective": "Why now for Immix Biopharma's therapies?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.6, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/19", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/20", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "Includes detailed source citations and disclaimer regarding cross-trial comparisons.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/21", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide uses a comparison table framework to highlight NXC-201's competitive advantage in safety (lower ICANS/CRS) and efficacy (higher ORR/CR).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/22", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-22", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "traction", "function": "show_traction", "notes": "The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/23", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 23, "from": 10, "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "traction", "function": "show_traction", "notes": "The chart demonstrates deepening clinical responses over time, with sCR/CR increasing from 50% to 83%.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/24", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-24", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "appendix_data", "function": "analyze_data", "notes": "The table highlights clinical safety data for NXC-201, showing low incidence of severe adverse events.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/25", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide highlights specific safety metrics for two dosage groups (100x10^6 and 300x10^6 cells).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/26", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "roadmap", "function": "plan_implementation", "notes": "Includes a footer citing FDA approval precedents for patient population sizes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/27", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 28, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The diagram illustrates a standard 3+3 or similar dose escalation design.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/28", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-28", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 29, "slideType": "section_divider", "function": "transition", "notes": "The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/29", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-29", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 30, "slideType": "solution", "function": "present_solution", "notes": "Includes a complex biological pathway diagram and three distinct data visualizations (line chart, scatter plot, bar chart) supporting the efficacy claims.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/30", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-30", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 31, "slideType": "traction", "function": "show_traction", "notes": "The slide uses bar charts to compare IMX-110 performance against standard drugs like Trabectedin and a 4-drug combination.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/31", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "traction", "function": "show_traction", "notes": "Includes a scientific mechanism of action diagram showing iMX-110 effects on tumor microenvironment.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/32", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "traction", "function": "show_traction", "notes": "Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor regression.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/33", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 34, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/34", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 35, "slideType": "traction", "function": "show_traction", "notes": "Includes waterfall charts and longitudinal patient response plots; highlights PFS (progression-free survival) and line of therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/35", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 36, "slideType": "problem_statement", "function": "frame_problem", "notes": "The slide uses a bubble chart to map mPFS against patient treatment history and a table to detail clinical outcomes across lines of therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/36", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-a698-70b1-b3ba-29e176396a9c", "docSlug": "63ec8e773c9b43e7b033b64167026114", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 37, "slideType": "traction", "function": "show_traction", "notes": "The chart visualizes a single data point (4 months mPFS at 100% pre-treated status) while the table provides detailed clinical trial outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/37", "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c", "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }